 This is a Phase II, single-center, single-arm, open-label, feasibility trial using a fixed dose combination of netupitant and palonosetron Akynzeo in the treatment of refractory CINV. The primary aim of this study is feasibility, defined as 70 completion rate of all study procedures over 7 days. 